BLNP 003
Alternative Names: BLNP-003Latest Information Update: 28 Feb 2021
At a glance
- Originator BL-&-H
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cryopyrin-associated periodic syndromes; Rheumatoid arthritis
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for clinical-Phase-Unknown development in Cryopyrin associated Periodic Syndromes in South Korea
- 28 Feb 2021 No recent reports of development identified for clinical-Phase-Unknown development in Rheumatoid-arthritis in South Korea
- 20 Feb 2019 BLNP 003 is still in clinical development for Rheumatoid arthritis and Cryopyrin associated Periodic Syndromes, in South Korea (BL & N pipeline, February 2019)